Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Johnson and Johnson
Merck
Dow

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,900,406

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,900,406
Title: Use of antibiotics of the type 2-deoxystreptamine substituted with aminosugars to inhibit growth of microorganisms containing group I introns
Abstract:The invention described herein provides for methods of screening for compounds that can be used to prevent or inhibit the growth of microbial eukaryotes, particularly plant or animal pathogens. The screening methods of the invention involve the step of screening compounds for the ability to inhibit Group I intron I splicing. In addition, to directly screening for compounds that inhibit Group I intron splicing, the screening methods of the invention include screening for compounds that bind to prokaryotic 16S ribosomal RNA because of the correlation, described herein, between group I intron inhibition and binding to prokaryotic 16S ribosomal RNA. The range of possible compounds for screening by the screening methods of the invention is preferably limited to 2-deoxystreptamine derivatives. Another aspect of the invention is to provide methods of treating or preventing infections with eukaryotic microbes by administering an effective amount of a compound that inhibits group I intron splicing. These compounds may be obtained by the screening methods of the invention.
Inventor(s): von Ahsen; Uwe (Santa Cruz, CA), Davies; Julian E. (Vancouver, CA), Schroeder; Renee (Vienna, AT)
Assignee: NZYM, Inc. (San Leandro, CA)
Application Number:08/255,611
Patent Claims:1. A method for inhibiting a eukaryotic microbial infection in a subject, comprising administering an effective amount of an aminoglycoside to the subject.

2. The method of claim 1 in which the eukaryotic microbe contains a group I intron.

3. The method of claim 1 in which the eukaryotic microbe is a fungus.

4. The method of claim 1 in which the hexose nucleus of the aminoglycoside is 2-deoxystreptamine.

5. The method of claim 4 in which the amino sugar substitutions are at positions 4 and 5.

6. The method of claim 4 in which the amino sugar substitutions are at positions 4 and 6.

7. The method of claim 1 in which the aminoglycoside is selected from the group consisting of gentamicin C.sub.la, gentamicin C.sub.2, gentamicin C.sub.1, gentamicin B, G418, tobramycin, kanamycin A, kanamycin B, kanamycin C, neamine, ribostamycin, neomycin B, paromomycin B, sisomicin, 5-epi-sisomicin, dihydrosisomicin, and 1-N-acetyl-sisomicin.

8. A method for inhibiting growth of a eukaryotic microbe, comprising contacting the microbe with an aminoglycoside.

9. The method of claim 8 in which the eukaryotic microbe contains a group I intron.

10. The method of claim 8 in which the eukaryotic microbe is a fungus.

11. The method of claim 8 in which the hexose nucleus of the aminoglycoside is 2-deoxystreptamine.

12. The method of claim 11 in which the amino sugar substitutions are at positions 4 and 5.

13. The method of claim 11 in which the amino sugar substitutions are at positions 4 and 6.

14. The method of claim 8 in which the aminoglycoside is selected from the group consisting of gentamicin C.sub.la, gentamicin C.sub.2, gentamicin C.sub.1, gentamicin B, G418, tobramycin, kanamycin A, kanamycin B, kanamycin C, neamine, ribostamycin, neomycin B, paromomycin B, sisomicin, 5-epi-sisomicin, dihydrosisomicin, and 1-N-acetyl-sisomicin.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Austria1375/91Jul 9, 1991

Details for Patent 5,900,406

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial NZYM, Inc. (San Leandro, CA) 2016-05-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial NZYM, Inc. (San Leandro, CA) 2016-05-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial NZYM, Inc. (San Leandro, CA) 2016-05-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Moodys
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.